Some of the world's biggest pharmaceutical companies are cutting back on their research programs as their most lucrative patents near expiration. With generics likely to wipe out billions of dollars in revenue, the companies are increasingly buying up predesigned drugs from outside suppliers, effectively moving from the research business into the drug-distribution business. "Science really doesn't pay any more," says one young researcher.

Full Story:

Related Summaries